Hira Mian - McMaster Experts

Affiliations

Faculty of Health Sciences, McMaster University
Full-Time Member, Escarpment Cancer Research Institute (ECRI), Faculty of Health Sciences
Associate Member, Health Research Methods, Evidence, and Impact, Faculty of Health Sciences
Associate Professor, Oncology, Faculty of Health Sciences

Scholarly Activity in McMaster Experts

Co-author Network

Scholarly Activity
Contact
View All

selected scholarly activity

chapters
- Haemopoietic Stem Cell Processing and Storage. 455-465. 2017
conferences
- 316P First evidence of olaparib maintenance therapy in patients with newly diagnosed BRCA wild-type ovarian cancer: A real-world multicenter study. Annals of Oncology. S1594-S1595. 2023
- INTERNATIONAL DIFFERENCES IN BASELINE CHARACTERISTICS AND PRACTICE PATTERNS IN PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA UNDERGOING UPFRONT AUTOLOGOUS STEM CELL TRANSPLANTATION. Bone Marrow Transplantation. 479-479. 2023
- NO EVIDENCE FOR IMPROVED OVERALL SURVIVAL OR PROGRESSION-FREE SURVIVAL IN MULTIPLE MYELOMA PATIENTS AGED 70-75 UNDERGOING AUTOLOGOUS STEM CELL TRANSPLANTATION COMPARED TO A NON-TRANSPLANT STRATEGY. Bone Marrow Transplantation. 366-367. 2023
- WORLDWIDE NETWORK FOR BLOOD AND MARROW TRANSPLANTATION GLOBAL STUDY ON BASELINE CHARACTERISTICS/CLINICAL OUTCOMES IN MULTIPLE MYELOMA PATIENTS UNDERGOING ASCT, A STUDY OFF 61,725 PATIENTS. Bone Marrow Transplantation. 479-480. 2023
- Comparative analysis of outcomes in patients with CRAB versus SLiM criteria at diagnosis of multiple myeloma. Clinical Lymphoma, Myeloma and Leukemia. S120-S121. 2023
- Development and validation of a prognostic survival model with patient reported outcomes for older adults with multiple myeloma. Clinical Lymphoma, Myeloma and Leukemia. S24-S24. 2023
- Outcomes of third-line therapy in multiple myeloma patients: a report from the Canadian myeloma research group (CMRG). Clinical Lymphoma, Myeloma and Leukemia. S197-S197. 2023
- Rationale and design of three ongoing phase 1/2 trials of modakafusp alfa, an innate immunity enhancer, in patients with multiple myeloma: The innovate clinical development program. Clinical Lymphoma, Myeloma and Leukemia. S147-S147. 2023
- Real-world outcomes in myeloma patients with t(11;14): a matched comparison using the Canadian myeloma research group national clinical database. Clinical Lymphoma, Myeloma and Leukemia. S215-S215. 2023
- Belantamab Mafodotin in Combination with Pomalidomide and Dexamethasone Demonstrates Durable Responses in Triple Class Exposed/Refractory Multiple Myeloma. Blood. 7306-7307. 2022
- Causes of Death Among Patients with Multiple Myeloma: A 10 Year Longitudinal Analysis of a Population-Based Cohort in Ontario, Canada. Blood. 427-429. 2022
- Impact of Daratumumab-Containing Regimens in Outcomes of Subsequent Treatments of Relapsed Multiple Myeloma in Real-World Practice from the Canadian Myeloma Research Group Database. Blood. 7192-7194. 2022
- Impact of Maintenance Therapy after Salvage Autologous Stem Cell Transplantation in Relapsed Multiple Myeloma. Blood. 10002-10004. 2022
- International Differences in Baseline Characteristics and Practice Patterns in Patients with NEWLY Diagnosed Multiple Myeloma Undergoing Upfront Autologous STEM Cell Transplantation. Blood. 5225-5227. 2022
- Need for Dynamic Frailty Risk Assessment Among Older Adults with Multiple Myeloma: A Population-Based Cohort Study. Blood. 423-424. 2022
- Prognostic Value of Translocation 11;14 in Patients with Relapsed/Refractory Myeloma Receiving Anti-CD38 Therapy. Blood. 5223-5224. 2022
- Real World Data on Outcomes of Anti-CD38 Antibody Refractory, Including Triple Class Refractory, Patients with Multiple Myeloma: A Multi-Institutional Report from the Canadian Myeloma Research Group (CMRG) Database. Blood. 4287-4289. 2022
- Real-World Results of Autologous Stem Cell Transplantation in Newly Diagnosed Patients with Multiple Myeloma: A Multi-Institutional Report from the Canadian Myeloma Research Group (CMRG) Database. Blood. 289-291. 2022
- Variable Frailty Categorization Among Real-World Patient with Multiple Myeloma: A Prospective Cohort Study (MFRAIL). Blood. 2395-2396. 2022
- Worldwide Network for Blood and Marrow Transplantation (WBMT) Global Study on Baseline Characteristics and Clinical Outcomes in NEWLY Diagnosed Multiple Myeloma Patients Undergoing Upfront Autologous STEM Cell Transplantation, a Study Off 61,725 Patients from 629 Centers. Blood. 4839-4842. 2022
- International differences in baseline characteristics and practice patterns in newly diagnosed multiple myeloma (MM) patients undergoing upfront autologous stem cell transplantation. Bone Marrow Transplantation. 44-45. 2022
- Gender disparities in multiple myeloma publications. eJHaem. 966-969. 2022
- Global Myeloma Trial Participation and Drug Access in the Era of Novel Therapies. Journal of Global Oncology. e2200119. 2022
- OAB-042: The impact of marginalization on treatment receipt and overall survival in newly diagnosed multiple myeloma patients in Ontario: a population-based cohort study. Clinical Lymphoma, Myeloma and Leukemia. S25-S26. 2022
- Outcomes of transplant-ineligible myeloma patients using bortezomib/lenalidomide-containing regimens in the real world: a report from the Canadian Myeloma Research Group Database. Clinical Lymphoma, Myeloma and Leukemia. S145-S146. 2022
- P-136: Global myeloma trial participation and drug access in the era of novel therapies. Clinical Lymphoma, Myeloma and Leukemia. S110-S110. 2022
- P-191: The prevalence and outcomes of frail older adults in clinical trials in multiple myeloma: a systematic review. Clinical Lymphoma, Myeloma and Leukemia. S140-S140. 2022
- P-201: Outcomes of transplant-ineligible myeloma patients using bortezomib/lenalidomidecontaining regimens in the real world: a report from the Canadian Myeloma Research Group Database. Clinical Lymphoma, Myeloma and Leukemia. S145-S146. 2022
- P-261: Treatment attrition rates in multiple myeloma (MM): a Canadian Myeloma Research Group (CMRG) analysis. Clinical Lymphoma, Myeloma and Leukemia. S180-S181. 2022
- The prevalence and outcomes of frail older adults in clinical trials in multiple myeloma: a systematic review. Clinical Lymphoma, Myeloma and Leukemia. S140-S140. 2022
- Treatment attrition rates in multiple myeloma (MM): a Canadian Myeloma Research Group (CMRG) analysis. Clinical Lymphoma, Myeloma and Leukemia. S180-S181. 2022
- Gender disparities in multiple myeloma publications.. Journal of Clinical Oncology. e23000-e23000. 2022
- Quality of end-of-life care for patients with multiple myeloma: A 12-year analysis of a population-based cohort.. Journal of Clinical Oncology. 2022
- Quality of end-of-life care for patients with multiple myeloma: A 12-year analysis of a population-based cohort.. Journal of Clinical Oncology. 12031-12031. 2022
- Part 1 Results of a Dose-Finding Study of Belantamab Mafodotin in Combination with Pomalidomide and Dexamethasone for the Treatment of Relapsed/Refractory Multiple Myeloma (RRMM). Blood. 2021
- Is Symptom Burden Associated with Health Care Utilization: A Longitudinal Population-Based Cohort Study of Transplant Ineligible Patients with Newly Diagnosed Multiple Myeloma. Blood. 116-116. 2021
- Lenalidomide Dosing and Outcomes in Transplant-Ineligible Patients with Newly-Diagnosed Multiple Myeloma: A Multi-Institutional Report from the Canadian Myeloma Research Group (CMRG) Database. Blood. 4721-4721. 2021
- Part 1 Results of a dose finding study of Belantamab Mafodotin (GSK2857916) in combination with Pomalidomide (POM) and Dexamethasone (DEX) for the treatment of Relapsed/Refractory Multiple Myeloma. Blood. 1653-1653. 2021
- Cardiovascular events among recipients of hematopoietic stem cell transplantation. European Heart Journal. ehab724.2876. 2021
- Cardiovascular events among recipients of hematopoietic stem cell transplantation. European Heart Journal. 2876-2876. 2021
- Extended follow-up safety and efficacy results of Belantamab mafodotin (Belamaf) 1.92 mg/kg or 2.5 mg/kg combined with POM and DEX for the treatment of relapsed/refractory Multiple Myeloma. Clinical Lymphoma, Myeloma and Leukemia. S162-S162. 2021
- P-222: Extended follow-up safety and efficacy results of Belantamab mafodotin (Belamaf) 1.92 mg/kg or 2.5 mg/kg combined with POM and DEX for the treatment of relapsed/refractory Multiple Myeloma. Clinical Lymphoma, Myeloma and Leukemia. S162-S162. 2021
- Decision making factors that influence treatment options for an autologous stem cell transplant for older adults (aged 65-75) with Newly Diagnosed Multiple Myeloma: A Mixed Methods.. Blood. 13-13. 2020
- Efficacy of Daratumumab Containing Regimens Post Lenalidomide Maintenance in Transplant Eligible Patients: Real-World Experience from the Canadian Myeloma Research Group Database. Blood. 26-27. 2020
- Is tandem ASCT needed in MM patients with high risk cytogenetics in the era of maintenance therapy? Results from the Canadian Myeloma Research Group (CMRG) Database.. Blood. 18-19. 2020
- Novel Single Panel Method for Minimal Residual Disease Detection for Plasma Cells By Flow Cytometry. Blood. 6-7. 2020
- Sequential use of Carfilzomib and Pomalidomide in Relapsed Multiple Myeloma: A Multi-Institutional Report from the Canadian Myeloma Research Group (CMRG) Database.. Blood. 5-7. 2020
- Symptom Burden in Transplant Ineligible Patients with Newly Diagnosed Multiple Myeloma: A Population-Based Study of Patient-Reported Outcomes. Blood. 30-31. 2020
- Trajectory of Symptoms after Autologous Stem Cell Transplant Among Patients with Multiple Myeloma: A Population-Based Study. Blood. 1-2. 2020
- Geriatric Assessment and Frailty Changes in Older Patients with Newly-Diagnosed Multiple Myeloma Undergoing Treatment. Blood. 4774-4774. 2019
- Undertreatment of Older Patients with Newly-Diagnosed Multiple Myeloma: Real World Evidence from a Canadian Registry Cohort. Blood. 268-268. 2019
- GERIATRIC ASSESSMENT CHANGES IN OLDER PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA UNDERGOING TREATMENT. Journal of Geriatric Oncology. S73-S74. 2019
- Quality of Life Assessment in Older Patients with Newly-Diagnosed Multiple Myeloma. Clinical Lymphoma, Myeloma and Leukemia. e232-e233. 2019
- Autoimmune HIT due to apheresis catheter heparin flushes for stem cell harvesting before autotransplantation for myeloma. Blood. 1679-1682. 2017
- The laboratory profile that predicts favorable outcome after Eculizumab therapy in patients with clinical features compatible with atypical hemolytic uremic syndrome. Journal of Thrombosis and Haemostasis. 712-712. 2015
- Characterization of Pulmonary Compliance in Sickle Cell Patients Revealed Wide Variability. Blood. 989-989. 2013
- Attrition rates in Multiple Myeloma: A Canadian Myeloma Research Group
- Duration of Eculizumab therapy for a clinical response in atypical hemolytic uremic syndrome.
- Geriatric assessment and frailty changes in older patients with Newly-Diagnosed Multiple Myeloma.
- Quality of life assessment in older patients with Newly Diagnosed Multiple Myeloma.
- Survival and outcomes of Newly-Diagnosed Multiple Myeloma patients stratified by transplant status diagnosed between 2007-2018: Real-World Analysis from the Canadian Myeloma Research Group
- Trajectory of symptoms after autologous stem cell transplant among patients with Multiple Myeloma: A Population-Based Study
- Trends in autologous hematopoietic stem cell transplant in older patients with Multiple Myeloma 2000-2017: The Canadian Experience
journal articles
- Treatment Patterns and Outcomes of Multiple Myeloma Patients Undergoing Second-Line Therapy: A Canadian Myeloma Research Group (CMRG) Analysis.. Clinical Lymphoma, Myeloma and Leukemia. 25:e491-e500.e1. 2025
- Long-term efficacy and safety of etentamig, a B-cell maturation antigen (BCMA) bispecific antibody in patients with relapsed/refractory multiple myeloma (RRMM).. Journal of Clinical Oncology. 43:7527-7527. 2025
- Minimal Residual Disease Testing Infrastructure in Multiple Myeloma: Guidance for Clinical Trial and Routine Practice Use in Canada.. Clinical Lymphoma, Myeloma and Leukemia. 25:e404-e410. 2025
- Outcomes of frailty subgroups of older adults (age ≥ 70) treated with teclistamab: an International Myeloma Foundation immunotherapy database real-world analysis.. Leukemia. 39:1252-1255. 2025
- [Not Available].. CANADIAN MEDICAL ASSOCIATION JOURNAL. 197:E459-E460. 2025
- A phase 2 randomized study of modakafusp alfa as a single agent in patients with relapsed/refractory multiple myeloma.. Blood. blood.2024027873. 2025
- A Qualitative Study Exploring the Rehabilitation Experience of Individuals with a Previous Diagnosis of Cancer and/or Sepsis, Their Caregivers, and Health Providers.. Healthcare (Switzerland). 13:822. 2025
- Real-world evaluation of teclistamab for the treatment of relapsed/refractory multiple myeloma (RRMM): an International Myeloma Working Group Study.. Blood Cancer Journal. 15:53. 2025
- Let's Agree to Disagree: Reflections From the Smoldering Multiple Myeloma Session at the International Myeloma Society Study Summit.. Clinical Lymphoma, Myeloma and Leukemia. 25:240-242. 2025
- Updates on myeloma in older adults: Conference summary from the 2024 International Myeloma Society annual meeting.. Journal of Geriatric Oncology. 16:102199. 2025
- First Line Treatment of Newly Diagnosed Transplant Eligible Multiple Myeloma Recommendations From a Canadian Consensus Guideline Consortium.. Clinical Lymphoma, Myeloma and Leukemia. 25:e151-e172. 2025
- International myeloma working group immunotherapy committee recommendation on sequencing immunotherapy for treatment of multiple myeloma.. Leukemia. 39:543-554. 2025
- Treatment of elderly and frail myeloma patients.. Presse Medicale. 54:104266. 2025
- Hypercalcemia in MGUS: keep the differential diagnosis broad.. Blood. 145:904-905. 2025
- Bispecific antibody toxicities.. CANADIAN MEDICAL ASSOCIATION JOURNAL. 197:E190. 2025
- Evaluating early intervention in smoldering myeloma clinical trials: a systematic review.. Oncologist. 30:oyae219. 2025
- A Prognostic Symptom Model Incorporating Patient-Reported Symptoms for Transplant-Ineligible Patients with Multiple Myeloma.. Cancers. 17:489. 2025
- Frailty measures in multiple myeloma: evaluating the impact on outcomes and quality-of-life in clinical trials and real-world practice.. Leukemia and Lymphoma. 66:190-203. 2025
- Comparing the clinical trial efficacy versus real-world effectiveness of treatments for multiple myeloma: a population-based study.. Haematologica. 110:228-233. 2025
- Optimizing multiple Myeloma clinical trials: research direction, addressing limitations, and strategies for improvement.. Leukemia and Lymphoma. 66:16-25. 2025
- Patient reported outcomes with earlier use of chimeric antigen receptor-T cell therapy in multiple myeloma.. The Lancet Haematology. 12:e6-e8. 2025
- Quadruplet regimens for patients with newly diagnosed multiple myeloma: a systematic review and meta-analysis.. Blood Advances. 8:5993-6002. 2024
- Cardiovascular Considerations During Cancer Therapy: Gaps in Evidence and JACC: CardioOncology Expert Panel Recommendations.. JACC: CardioOncology. 6:815-834. 2024
- A Phase 1b Study of Step-up Dosing with ABBV-383, a B-Cell Maturation Antigen (BCMA) x CD3 Bispecific Antibody, in Patients with Relapsed or Refractory Multiple Myeloma. Blood. 144:1985. 2024
- A Phase I/II Study of AZD0305, a Novel Antibody-Drug Conjugate (ADC) Targeting GPRC5D, in Patients with Relapsed/Refractory Multiple Myeloma (RRMM). Blood. 144:2000.2-2000.2. 2024
- Exposure-Response (ER) and Pharmacokinetic/Pharmacodynamic (PK/PD) Analyses for Optimal Step-up Dose (SUD) Selection to Improve Cytokine Release Syndrome (CRS) Safety Profile of Abbv-383 in Patients with Relapsed or Refractory Multiple Myeloma (RRMM). Blood. 144:1994. 2024
- Long-Term Follow-up of Real-World Teclistamab Therapy for Relapsed/Refractory Multiple Myeloma from the IMWG Immunotherapy Working Group Committee. Blood. 144:5166-5166. 2024
- Longitudinal Changes in Cognition in Older Individuals Receiving Lymphoma-Directed Therapy: A Pilot Feasibility Study. Blood. 144:3753-3753. 2024
- Maintenance after Autologous Hematopoietic Cell Transplantation Improves Overall Survival and Progression Free Survival Regardless of Disease Stage at Transplant in Newly Diagnosed Myeloma Patients: A Global, Real-World Analysis from the Worldwide Network for Blood and Marrow Transplantation Global Study. Blood. 144:2379-2381. 2024
- Monumental-6: A Phase 3 Study of Talquetamab plus Pomalidomide or Talquetamab plus Teclistamab Vs Elotuzumab plus Pomalidomide plus Dexamethasone (EPd) or Pomalidomide plus Bortezomib plus Dexamethasone (PVd) in Patients with Relapsed/Refractory Multiple Myeloma Who Received 1-4 Prior Lines of Therapy, Including Lenalidomide and an Anti-CD38 Monoclonal Antibody. Blood. 144:47571-47572. 2024
- Outcomes of Frailty Subgroups Treated with Teclistamab in the Real-World: An International Myeloma Foundation Study Database Analysis. Blood. 144:704-705. 2024
- Randomized Phase 2 Dose Optimization Trial of Modakafusp Alfa in Relapsed/Refractory Multiple Myeloma (RRMM). Blood. 144:3355-3355. 2024
- Real World Evidence of Outcomes of Patients Treated with Talquetamab in a Heavily Pretreated Population with Multiple Myeloma with High Exposure to Prior BCMA Therapies- a Report from the IMWG Consortium. Blood. 144:3368-3368. 2024
- Secondary Cancers Among Patients with Multiple Myeloma: A 15-Year Analysis of a Population-Based Cohort in Ontario, Canada. Blood. 144:5170.3-5170.3. 2024
- Trajectories of Frailty Categorization over Time Among Real-World Patients with Multiple Myeloma: A Prospective Cohort Study (MFRAIL). Blood. 144:703-704. 2024
- ULTRA FRAIL-MM Clinical Trial: Go-Slow Approach Incorporating Isatuximab, Lenalidomide and Dexamethasone for Ultra-Frail Newly Diagnosed Myeloma. Blood. 144:6916-6917. 2024
- Utilization of Multiple Myeloma Treatments in Developing Countries: Systematic Review and Meta-Analysis. Blood. 144:6986-6987. 2024
- Validation of the EBMT Multiple Myeloma Early Relapse Score within Worldwide Network for Blood and Marrow Transplantation (WBMT) Global Study. Blood. 144:4734-4735. 2024
- Disease Characteristics and Outcomes of 493 Young Myeloma Patients Treated With Modern Therapies: A Canadian Myeloma Research Group Database Study.. Cancer Medicine. 13:e70332. 2024
- Global characteristics and outcomes of autologous hematopoietic stem cell transplantation for newly diagnosed multiple myeloma: A study of the worldwide network for blood and marrow transplantation (WBMT).. American Journal of Hematology. 99:2084-2095. 2024
- Quadruplets in newly diagnosed transplant-ineligible multiple myeloma.. American Journal of Hematology. 99:2249-2252. 2024
- Impact of age on treatment utilization for newly diagnosed multiple myeloma: a nationwide retrospective cohort study.. Blood Cancer Journal. 14:181. 2024
- Still high risk? A review of translocation t(14;16) in multiple myeloma. American Journal of Hematology. 99:1979-1987. 2024
- Belantamab mafodotin, pomalidomide, and dexamethasone for triple class exposed/refractory relapsed multiple myeloma: a subgroup analysis of the ALGONQUIN trial.. Blood Cancer Journal. 14:155. 2024
- P-161 Gut Microbiota Differences Among Transplant Ineligible Patients With Newly-Diagnosed Multiple Myeloma Treated With dara-len-dex. Clinical Lymphoma, Myeloma and Leukemia. 24:s131-s132. 2024
- P-318 A Real-World Comparison of First-Line Regimens in Transplant Ineligible Patients with Multiple Myeloma. Clinical Lymphoma, Myeloma and Leukemia. 24:s217-s218. 2024
- P-354 Real-World Comparison of Progression Free Survival and Time to Next Therapy Endpoints in Newly Diagnosed Patients With Multiple Myeloma. Clinical Lymphoma, Myeloma and Leukemia. 24:s237-s238. 2024
- Patient-Reported Outcome Measures in Cancer Care. JAMA network open. 7:e2424793-e2424793. 2024
- Prevalence of geriatric impairments and frailty categorization among real-world patients with multiple myeloma: a prospective cohort study (MFRAIL). Leukemia and Lymphoma. 65:1167-1174. 2024
- Pomalidomide Use and Kidney Outcomes in Patients With Relapsed/Refractory Multiple Myeloma and Chronic Kidney Disease: A Real-World, Population-Based Cohort Study. Clinical Lymphoma, Myeloma and Leukemia. 24:e861-e869. 2024
- Tandem Autologous Stem Cell Transplantation Does Not Benefit High-Risk Myeloma Patients in the Maintenance Era: Real-World Results from The Canadian Myeloma Research Group Database. Transplantation and Cellular Therapy. 30:889-901. 2024
- A Prognostic Survival Model Incorporating Patient-Reported Outcomes for Transplant-Ineligible Patients With Multiple Myeloma. Oncologist. 29:519-526. 2024
- Long‐term follow‐up of outcomes including progression‐free survival 2 in patients with transplant‐ineligible multiple myeloma in the real‐world practice: A multi‐institutional report from the Canadian Myeloma Research Group (CMRG) database. eJHaem. 5:474-484. 2024
- Perspectives on geriatric oncology research presented at the 2023 American Society of Hematology Annual Meeting: Young International Society of Geriatric Oncology report. Journal of Geriatric Oncology. 15:101762-101762. 2024
- Treatment Pattern, Healthcare Resource Utilization and Symptom Burden Among Patients with Triple Class Exposed Multiple Myeloma: A Population-Based Cohort Study. Clinical Lymphoma, Myeloma and Leukemia. 24:e227-e234. 2024
- A structured oral chemotherapy teaching tool to improve adherence in adults with multiple myeloma: A pilot randomized controlled trial. Journal of Geriatric Oncology. 15:101735-101735. 2024
- Belantamab mafodotin, pomalidomide and dexamethasone in refractory multiple myeloma: a phase 1/2 trial. Nature Medicine. 30:543-551. 2024
- Alterations in chromosome 1q in multiple myeloma randomized clinical trials: a systematic review. Blood Cancer Journal. 14:20. 2024
- Translocation t(14;16) in multiple myeloma: gangster or just part of the gang?. Blood Cancer Journal. 14:7. 2024
- Real world data on outcomes of anti-CD38 antibody treated, including triple class refractory, patients with multiple myeloma: a multi-institutional report from the Canadian Myeloma Research Group (CMRG) Database. Blood Cancer Journal. 13:181. 2023
- Cancer-specific mortality in multiple myeloma: a population-based retrospective cohort study. Haematologica. 108:3384-3391. 2023
- MRD negativity: considerations for older adults with multiple myeloma. Blood Cancer Journal. 13:166. 2023
- Comparison of the Efficacy in Clinical Trials Versus Effectiveness in the Real-World of Treatments for Multiple Myeloma: A Population-Based Cohort Study. Blood. 142:541-541. 2023
- Disease Characteristics and Outcomes of 504 Young Patients Diagnosed with Multiple Myeloma Treated with Modern Therapies in Canada. Blood. 142:1954-1954. 2023
- Efficacy and Tolerance of Isatuximab, Cyclophosphamide, Bortezomib, and Dexamethasone (Isa-CBD) Induction Chemotherapy in Newly Diagnosed, Transplant Eligible Multiple Myeloma: Report of the Phase 2 Multi-Centre, Open Label Canadian Myeloma Research Group (CMRG)-008 Prospective Clinical Trial. Blood. 142:4751-4751. 2023
- Gain1q in Myeloma Randomized Clinical Trials- How Is It Reported and How Does It Impact Outcomes: A Systematic Review. Blood. 142:3363-3363. 2023
- Impact of Age on Outcome in Newly Diagnosed Multiple Myeloma Patients Undergoing Upfront Autologous Hematopoietic Cell Transplantation from the Worldwide Network for Blood and Marrow Transplantation Global Study. Blood. 142:785-785. 2023
- Prevention of Ocular Toxicity Using Protective Contact Lenses in Multiple Myeloma Patients Receiving Belantamab Mafodotin, Pomalidomide and Dexamethasone: A Sub-Study of the Cmrg-007 Trial. Blood. 142:4756-4756. 2023
- Real-World Treatment Patterns and Clinical Outcomes Among Triple-Class Exposed and B-Cell Maturation Antigen (BCMA) Exposed Multiple Myeloma Patients. Blood. 142:542-542. 2023
- Second Line Treatment and Outcomes of Patients with Multiple Myeloma: A Real World Multi-Institutional Report from the Canadian Myeloma Research Group (CMRG) Database. Blood. 142:3364-3364. 2023
- Treatment Patterns and Healthcare Resource Utilization Among Patients with Triple Class Exposed Multiple Myeloma: A Population-Based Cohort Study. Blood. 142:3774-3774. 2023
- Outcome of carfilzomib/pomalidomide‐based regimens after daratumumab‐based treatment in relapsed multiple myeloma: A Canadian Myeloma Research Group Database analysis. European Journal of Haematology. 111:815-823. 2023
- Risk of cancer-specific death among octogenarians with multiple myeloma: A population-based analysis. Journal of Geriatric Oncology. 14:101592-101592. 2023
- Characteristics of post hoc subgroup analyses of oncology clinical trials: a systematic review. JNCI Cancer Spectrum. 7:pkad100. 2023
- Real-world results of autologous stem cell transplantation in newly diagnosed multiple myeloma: a report from the Canadian Myeloma Research Group database. Blood Cancer Journal. 13:137. 2023
- A pilot study of adherence to lenalidomide among older patients with multiple myeloma. Journal of Geriatric Oncology. 14:101560-101560. 2023
- OA-39 Development and validation of a prognostic survival model with patient reported outcomes for older adults with multiple myeloma. Clinical Lymphoma, Myeloma and Leukemia. 23:S24-S24. 2023
- P-155 Comparative analysis of outcomes in patients with CRAB versus SLiM criteria at diagnosis of multiple myeloma. Clinical Lymphoma, Myeloma and Leukemia. 23:S120-S121. 2023
- P-203 Rationale and design of three ongoing phase 1/2 trials of modakafusp alfa, an innate immunity enhancer, in patients with multiple myeloma: The innovate clinical development program. Clinical Lymphoma, Myeloma and Leukemia. 23:S147-S147. 2023
- P-291 Outcomes of third-line therapy in multiple myeloma patients: a report from the Canadian myeloma research group (CMRG). Clinical Lymphoma, Myeloma and Leukemia. 23:S197-S197. 2023
- P-321 Real-world outcomes in myeloma patients with t(11;14): a matched comparison using the Canadian myeloma research group national clinical database. Clinical Lymphoma, Myeloma and Leukemia. 23:S215-S215. 2023
- Correction: Redefining attrition in multiple myeloma (MM): a Canadian Myeloma Research Group (CMRG) analysis. Blood Cancer Journal. 13:129. 2023
- Cardiac Interventions in Patients With Active, Advanced Solid and Hematologic Malignancies. JACC: CardioOncology. 5:415-430. 2023
- Socioeconomic marginalization and health outcomes in newly diagnosed multiple myeloma: A population‐based cohort study. American Journal of Hematology. 98:E197-E199. 2023
- Redefining attrition in multiple myeloma (MM): a Canadian Myeloma Research Group (CMRG) analysis. Blood Cancer Journal. 13:111. 2023
- Impact of bortezomib‐based versus lenalidomide maintenance therapy on outcomes of patients with high‐risk multiple myeloma. Cancer. 129:2179-2191. 2023
- Impact of second primary malignancy post–autologous transplantation on outcomes of multiple myeloma: a CIBMTR analysis. Blood Advances. 7:2746-2757. 2023
- Frailty and survival among veterans treated with abiraterone or enzalutamide for metastatic castration-resistant prostate cancer. Journal of Geriatric Oncology. 14:101520-101520. 2023
- Dynamic frailty risk assessment among older adults with multiple myeloma: A population-based cohort study. Blood Cancer Journal. 13:76. 2023
- Cardiovascular events among recipients of hematopoietic stem cell transplantation-A systematic review and meta-analysis. Bone Marrow Transplantation. 58:478-490. 2023
- First Line Treatment of Newly Diagnosed Transplant Ineligible Multiple Myeloma: Recommendations from the Canadian Myeloma Research Group Consensus Guideline Consortium. Clinical Lymphoma, Myeloma and Leukemia. 23:340-354. 2023
- Health-related quality of life in early-stage Hodgkin lymphoma: a longitudinal analysis of the ABVD arm in the randomized controlled trial HD.6. Supportive Care in Cancer. 31:256. 2023
- Real‐world data on lenalidomide dosing and outcomes in patients newly diagnosed with multiple myeloma: Results from the Canadian Myeloma Research Group Database. Cancer Medicine. 12:4357-4362. 2023
- Prognostic value of translocation 11;14 in patients with relapsed/refractory myeloma receiving anti-CD38 therapy. Blood Cancer Journal. 12:168. 2022
- Quality of end‐of‐life care in multiple myeloma: A 13‐year analysis of a population‐based cohort in Ontario, Canada. British Journal of Haematology. 199:688-695. 2022
- Teclistamab in Relapsed or Refractory Multiple Myeloma. New England Journal of Medicine. 387:1721-1723. 2022
- Teclistamab in Relapsed or Refractory Multiple Myeloma. Reply.. New England Journal of Medicine. 387:1722-1723. 2022
- Carfilzomib usage patterns and outcomes in patients with relapsed multiple myeloma: A multi‐institutional report from the Canadian Myeloma Research Group (CMRG) Database. eJHaem. 3:1252-1261. 2022
- What do hematology residents know about caring for older adults with cancer? A national survey of Canadian hematology residents' knowledge and interests. Journal of Geriatric Oncology. 13:1236-1240. 2022
- Survival and Outcomes of Newly Diagnosed Multiple Myeloma Patients Stratified by Transplant Status 2007-2018: Retrospective Analysis from the Canadian Myeloma Research Group Database. Clinical Lymphoma, Myeloma and Leukemia. 22:608-617. 2022
- Outcomes after autologous hematopoietic cell transplantation in POEMS syndrome and comparison with multiple myeloma. Blood Advances. 6:3991-3995. 2022
- Outcomes of daratumumab in the treatment of multiple myeloma: A retrospective cohort study from the Canadian Myeloma Research Group Database. British Journal of Haematology. 198:93-102. 2022
- Financial toxicity in hematological malignancies: a systematic review. Blood Cancer Journal. 12:74. 2022
- Just the facts: how to diagnose and manage patients with multiple myeloma in the emergency department?. Canadian Journal of Emergency Medicine. 24:256-258. 2022
- Sequential Use of Carfilzomib and Pomalidomide in Relapsed Multiple Myeloma: A Report from the Canadian Myeloma Research Group (CMRG) Database. Current Oncology. 29:1575-1582. 2022
- A second autologous hematopoietic cell transplantation is a safe and effective salvage therapy in select relapsed or refractory AL amyloidosis patients. Bone Marrow Transplantation. 57:295-298. 2022
- Patient-reported outcome measures are associated with health care utilization in patients with transplant ineligible multiple myeloma: a population-based study. Blood Cancer Journal. 12:17. 2022
- Daratumumab in newly diagnosed MM — incorporating lessons learnt from CASSIOPEIA, MAIA and beyond. Nature Reviews Clinical Oncology. 19:3-4. 2022
- Decision-making factors for an autologous stem cell transplant for older adults with newly diagnosed multiple myeloma: A qualitative analysis. Frontiers in Oncology. 12:974038. 2022
- Efficacy of Daratumumab-Containing Regimens Among Patients With Multiple Myeloma Progressing on Lenalidomide Maintenance: Retrospective Analysis. Frontiers in Oncology. 12:826342. 2022
- Maintenance therapy after second autologous hematopoietic cell transplantation for multiple myeloma. A CIBMTR analysis. Bone Marrow Transplantation. 57:31-37. 2022
- A new world of residency education: game changers and proven practices. Canadian Medical Education Journal. 12:157-246. 2021
- Trajectory of Symptoms in Patients Undergoing Autologous Stem Cell Transplant for Multiple Myeloma: A Population-Based Cohort Study of Patient-Reported Outcomes. Clinical Lymphoma, Myeloma and Leukemia. 21:e714-e721. 2021
- Symptom burden in transplant-ineligible patients with newly diagnosed multiple myeloma: a population-based cohort study. Haematologica. 106:1991-1994. 2021
- External validation of the FIRST trial’s simplified frailty score in a population-based cohort. Leukemia. 35:1823-1827. 2021
- Disparities in treatment patterns and outcomes among younger and older adults with newly diagnosed multiple myeloma: A population-based study. Journal of Geriatric Oncology. 12:508-514. 2021
- Renal failure among multiple myeloma patients utilizing carfilzomib and associated factors in the “real world”. Annals of Hematology. 100:1261-1266. 2021
- Transplant-ineligible newly diagnosed multiple myeloma: Current and future approaches to clinical care: A Young International Society of Geriatric Oncology Review Paper. Journal of Geriatric Oncology. 12:499-507. 2021
- Burden of Treatment Among Older Adults With Newly Diagnosed Multiple Myeloma. Clinical Lymphoma, Myeloma and Leukemia. 21:e152-e159. 2021
- Geriatric assessment and quality of life changes in older adults with newly diagnosed multiple myeloma undergoing treatment. Journal of Geriatric Oncology. 11:1279-1284. 2020
- Maintenance therapy in transplant ineligible adults with newly‐diagnosed multiple myeloma: A systematic review and meta‐analysis. European Journal of Haematology. 105:626-634. 2020
- Caring for older patients with cancer during the COVID-19 pandemic: A Young International Society of Geriatric Oncology (SIOG) global perspective. Journal of Geriatric Oncology. 11:1175-1181. 2020
- Registry Data and Conditioning Therapy for Allogeneic Hematopoietic Cell Transplant and Lymphoma. JAMA Oncology. 6:989-989. 2020
- Simplified frailty assessment tools: are we really capturing frailty or something else?. Leukemia. 34:1967-1969. 2020
- Caring for older adults with multiple myeloma during the COVID-19 Pandemic: Perspective from the International Forum for Optimizing Care of Older Adults with Myeloma. Journal of Geriatric Oncology. 11:764-768. 2020
- Perspectives from the Cancer and Aging Research Group: Caring for the vulnerable older patient with cancer and their caregivers during the COVID-19 crisis in the United States. Journal of Geriatric Oncology. 11:753-760. 2020
- Geriatric hematology research at the 2019 American Society of Hematology annual meeting: Young International Society of geriatric oncology perspective paper. Journal of Geriatric Oncology. 11:735-739. 2020
- Arti Hurria and the progress in integrating the geriatric assessment into oncology: Young International Society of Geriatric Oncology review paper. Journal of Geriatric Oncology. 11:203-211. 2020
- Adherence to Lenalidomide in Older Adults With Newly Diagnosed Multiple Myeloma. Clinical Lymphoma, Myeloma and Leukemia. 20:98-104.e1. 2020
- The Evolving Field of Bone Imaging in Multiple Myeloma: Is it Time to Abandon Skeletal Surveys?. Current Oncology. 27:10-11. 2020
- Autologous stem cell transplant in older patients (age ≥ 65) with newly diagnosed multiple myeloma: A systematic review and meta-analysis. Journal of Geriatric Oncology. 11:93-99. 2020
- Geriatric Assessment and Frailty Scores Predict Mortality in Myeloma: Systematic Review and Meta-analysis. Clinical Lymphoma, Myeloma and Leukemia. 19:488-496.e6. 2019
- COMPARISON OF FRAILTY SCORES IN NEWLY DIAGNOSED PATIENTS WITH MULTIPLE MYELOMA: A REVIEW. Journal of Frailty and Aging. 8:1-7. 2019
- Development of a Medicare Health Outcomes Survey Deficit-Accumulation Frailty Index and Its Application to Older Patients With Newly Diagnosed Multiple Myeloma. JCO clinical cancer informatics. 2:1-13. 2018
- Novel Treatments for Multiple Myeloma: What Role Do They Have in Older Adults?. Drugs and Aging. 35:289-302. 2018
- The relationship of CD34+ dosage and platelet recovery following high dose chemotherapy and autologous CD34+ reinfusion in multiple myeloma. Transfusion and Apheresis Science. 56:552-557. 2017
- EspP, an Extracellular Serine Protease from Enterohemorrhagic E. coli, Reduces Coagulation Factor Activities, Reduces Clot Strength, and Promotes Clot Lysis. PLoS ONE. 11:e0149830-e0149830. 2016
- Optimal Manual Exchange Transfusion Protocol for Sickle Cell Disease: A Retrospective Comparison of Two Comprehensive Care Centers in the United Kingdom and Canada. Hemoglobin. 39:310-315. 2015
- Venous thrombosis in inflammatory bowel disease. CANADIAN MEDICAL ASSOCIATION JOURNAL. 187:55-55. 2015
- Crystal Structure of the Passenger Domain of the Escherichia coli Autotransporter EspP. Journal of Molecular Biology. 413:985-1000. 2011
- Mixed Variant Multicentric Castleman Disease Treated With Rituximab: Case Report. Journal of Pediatric Hematology/Oncology. 32:622-622. 2010
- Exploring the intersection of cancer, sepsis, and frailty: a scoping review. Discover Medicine. 1:56.
- PB2129: THE MODAKAFUSP ALFA IINNOVATE CLINICAL DEVELOPMENT PROGRAM: RATIONALE AND DESIGN OF 3 PHASE 1/2 TRIALS OF AN INNATE IMMUNITY ENHANCER FOR MULTIPLE MYELOMA (MM). HemaSphere. 7:e9860835-e9860835.
preprints
- A prospective study of adherence to lenalidomide for multiple myeloma using Medication Event Monitoring System (MEMS) caps 2022